Compare Amcor PLC (AMCR) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs BridgeBio Pharma Inc — how do they compare? Amcor PLC trades at $47.35 (market cap $21.78B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Amcor PLC is the larger of the two by market cap, and Amcor PLC pays a 5.52% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AMCR | BBIO | |
|---|---|---|
Market Cap | $21.78B | $16.61B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $90.17 |
52-Week Low | $36.69 | $47.29 |
Enterprise Value | $36.90B | $18.16B |
Dividend Yield | 5.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.86, up 1.7% today, near the consensus price target of $47.00. The stock shows bullish technical signals from moving averages, with RSI indicating mild overbought conditions. Recent quarters saw earnings beats, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. The company expanded its packaging facility in China and partnered with Kelpi for sustainable solutions, signaling growth initiatives.
Outlook is cautiously optimistic with analyst consensus at Buy (64%), but risks include margin pressure and high P/E of 38.44. Investment appeal hinges on earnings delivery and cost management amid competitive and macroeconomic headwinds.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
